Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC70	AS605240	2	72	sigmoid	sigmoid	HCC70 AS-605240 0 2 72	8	1.771	6.13	0.558	0.126	1.21	0.339	0.698	0.981	7.24e-06	NA	785.0	0.643	0.894	0.946	0.496	0.708	0.978	1.04e-05	NA
HCC38	BX-912	2	72	sigmoid	sigmoid	HCC38 BX-912 0 2 72	8	2.186	0.583	-0.229	0.251	0.648	-0.233	3.62	0.999	9.58e-10	NA	0.602	0.124	0.807	0.559	0.123	3.78	0.998	1.03e-08	NA
Hs 578T	PI103	1		sigmoid	sigmoid	Hs578T PI-103 1	8	2.062	0.131	-0.0743	0.433	0.182	-0.173	0.898	0.996	4.43e-08	NA	0.175	0.204	0.643	0.117	0.152	0.898	0.995	1.02e-07	NA
HCC38	PI103	1	72	sigmoid	sigmoid	HCC38 PI-103 0 1 72	8	1.782	0.755	0.222	0.201	0.601	0.12	1.2	0.996	4.45e-08	NA	1.39	0.416	0.839	0.494	0.359	1.23	0.995	1.01e-07	NA
HCC38	ZSTK474	1	72	sigmoid	sigmoid	HCC38 ZSTK474 0 1 72	8	1.742	2.47	0.456	0.132	1.34	0.202	0.843	0.991	7.12e-07	NA	9.02	0.575	0.893	1.0	0.426	0.869	0.99	1.01e-06	NA
HCC38	XL147	1	72	flat	flat	HCC38 pilaralisib 0 1 72	8	1.752	Inf	0.949	0.0257	0.0	0.949	0.01	-0.0703	1.0	0.973	Inf	0.955	0.978	0.0	0.955	0.01	-0.0701	1.0	0.977
HCC38	KIN001-244	2	72	flat	flat	HCC38 KIN001-244 0 2 72	8	2.210	Inf	0.948	0.0304	0.0	0.948	0.01	-0.0213	1.0	0.969	Inf	0.944	0.967	0.0	0.944	0.01	-0.0218	1.0	0.966
HCC38	Alpelisib	2	72	flat	flat	HCC38 alpelisib 0 2 72	8	2.086	Inf	0.848	0.0559	0.0	0.848	0.01	-0.0371	1.0	0.931	Inf	0.848	0.944	0.0	0.848	0.01	-0.0359	1.0	0.932
HCC38	XL147	2	72	flat	flat	HCC38 pilaralisib 0 2 72	8	2.194	Inf	0.938	0.0288	0.0	0.938	0.01	-0.0925	1.0	0.968	Inf	0.933	0.969	0.0	0.933	0.01	-0.0418	1.0	0.965
HCC38	AS605240	3	72	flat	flat	HCC38 AS-605240 0 3 72	8	1.343	Inf	0.958	-0.0162	0.0	0.958	0.01	-0.233	1.0	1.01	Inf	0.972	1.01	0.0	0.972	0.01	-0.235	1.0	1.01
BT-549	XL147	3	72	flat	flat	BT549 pilaralisib 0 3 72	8	1.772	Inf	0.933	0.0351	0.0	0.933	0.01	-0.0699	1.0	0.962	Inf	0.941	0.969	0.0	0.941	0.01	-0.0712	1.0	0.967
BT-549	XL147	2	72	flat	flat	BT549 pilaralisib 0 2 72	8	1.952	Inf	0.967	-0.00824	0.0	0.967	0.01	-0.000427	1.0	1.0	Inf	0.968	1.01	0.0	0.968	0.01	-0.000878	1.0	1.0
BT-549	XL147	1	72	flat	flat	BT549 pilaralisib 0 1 72	8	1.855	Inf	0.941	0.0385	0.0	0.941	0.01	-0.0931	1.0	0.954	Inf	0.946	0.965	0.0	0.946	0.01	-0.0808	1.0	0.958
HCC70	KIN001-244	2	72	flat	flat	HCC70 KIN001-244 0 2 72	8	1.684	Inf	0.898	-0.0201	0.0	0.898	0.01	0.508	0.119	1.01	Inf	0.916	1.02	0.0	0.916	0.01	-0.0458	1.0	1.01
HCC70	KIN001-244	3	72	flat	flat	HCC70 KIN001-244 0 3 72	8	2.472	Inf	0.916	0.0295	0.0	0.916	0.01	-0.0208	1.0	0.969	Inf	0.899	0.965	0.0	0.899	0.01	-0.00883	1.0	0.963
HCC70	XL147	1	72	flat	flat	HCC70 pilaralisib 0 1 72	8	1.396	Inf	1.05	-0.0406	0.0	1.05	0.01	-0.285	1.0	1.03	Inf	1.04	1.03	0.0	1.04	0.01	-0.295	1.0	1.02
HCC70	XL147	2	72	flat	flat	HCC70 pilaralisib 0 2 72	8	1.789	Inf	0.966	0.0311	0.0	0.966	0.01	-0.12	1.0	0.965	Inf	0.97	0.973	0.0	0.97	0.01	-0.121	1.0	0.969
HCC70	XL147	3	72	flat	flat	HCC70 pilaralisib 0 3 72	8	2.478	Inf	1.03	-0.0199	0.0	1.03	0.01	-0.318	1.0	1.02	Inf	1.03	1.03	0.0	1.03	0.01	-0.331	1.0	1.02
HCC1806	AZD-6482	1	72	flat	flat	HCC1806 AZD6482 0 1 72	8	2.748	Inf	1.0	0.00141	0.0	1.0	0.01	-0.00621	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
HCC1806	AZD-6482	2	72	flat	flat	HCC1806 AZD6482 0 2 72	8	2.833	Inf	1.0	0.00136	0.0	1.0	0.01	-0.0062	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00512	1.0	0.998
HCC1806	AZD-6482	3	72	flat	flat	HCC1806 AZD6482 0 3 72	8	3.201	Inf	1.0	0.00122	0.0	1.0	0.01	-0.0063	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
BT-549	Everolimus	2	72	flat	flat	BT549 everolimus 0 2 72	8	1.909	Inf	0.566	0.407	0.0	0.566	0.01	-0.646	1.0	0.594	Inf	0.627	0.648	0.0	0.627	0.01	-1.01	1.0	0.649
HCC1806	Alpelisib	1	72	flat	flat	HCC1806 alpelisib 0 1 72	8	2.771	Inf	0.918	0.0583	0.0	0.918	0.01	-0.337	1.0	0.94	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC1806	Alpelisib	2	72	flat	flat	HCC1806 alpelisib 0 2 72	8	2.856	Inf	0.921	0.0566	0.0	0.921	0.01	-0.336	1.0	0.941	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC1806	Alpelisib	3	72	flat	flat	HCC1806 alpelisib 0 3 72	8	3.224	Inf	0.93	0.0502	0.0	0.93	0.01	-0.335	1.0	0.948	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)